Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PARIS & BRISBANE, Calif.--(BUSINESS WIRE)--Regulatory News: Diaxonhit (Paris:ALEHT), the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap®) in Europe. AlloMap is XDx’s flagship diagnostic blood test used by physicians to identify heart transplant recipients who have a low probability of acute cellular rejection. AlloMap has been marketed in the United States since 2005 and is CLIA certified, FDA cleared and obtained CE marking in Europe in 2011.
Help employers find you! Check out all the jobs and post your resume.
